SELLAS Life Sciences Group Sees Unusually Large Options Volume (NASDAQ:SLS)

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) was the recipient of some unusual options trading on Monday. Investors purchased 42,324 call options on the company. This represents an increase of approximately 54% compared to the typical daily volume of 27,474 call options.

Institutional Investors Weigh In On SELLAS Life Sciences Group

Hedge funds have recently modified their holdings of the business. Everhart Financial Group Inc. purchased a new stake in shares of SELLAS Life Sciences Group during the 3rd quarter valued at approximately $533,000. Trustmark Bank Trust Department acquired a new stake in SELLAS Life Sciences Group during the third quarter worth $59,000. Beacon Pointe Advisors LLC purchased a new stake in SELLAS Life Sciences Group in the fourth quarter valued at $38,000. Anson Funds Management LP raised its position in SELLAS Life Sciences Group by 2,093.8% in the third quarter. Anson Funds Management LP now owns 6,032,938 shares of the company’s stock valued at $9,713,000 after purchasing an additional 5,757,938 shares during the period. Finally, Dagco Inc. acquired a new position in shares of SELLAS Life Sciences Group in the 4th quarter valued at $2,177,000. 17.38% of the stock is currently owned by institutional investors and hedge funds.

SELLAS Life Sciences Group Price Performance

Shares of NASDAQ:SLS opened at $4.74 on Wednesday. The business’s 50 day moving average price is $3.76 and its 200-day moving average price is $2.47. The firm has a market capitalization of $675.18 million, a PE ratio of -16.93 and a beta of 2.27. SELLAS Life Sciences Group has a 1 year low of $0.95 and a 1 year high of $5.18.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a report on Thursday, January 22nd. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, SELLAS Life Sciences Group has a consensus rating of “Hold” and an average price target of $7.00.

About SELLAS Life Sciences Group

SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms’ tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient’s own immune system to recognize and attack WT1-positive cancer cells.

The company’s lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1.